In total, GO-Bio funding has so far led to the founding of a company or the commencement of business operations in more than 44 cases.

In the last 30 years, a biotechnology sector with over 800 companies has emerged in Germany. Around 20 to 30 companies are added each year. With GO-Bio, the Federal Ministry of Education and Research is ensuring that promising start-ups can continue to emerge.

Between 2005 and 2023, the GO-Bio programme funded 57 projects from 723 project proposals in eight selection rounds. Of these, 21 projects also received funding in the second phase after successfully founding a company. Some teams also founded a company without taking advantage of a second GO-Bio funding phase.

In total, GO-Bio funding has so far led to the founding of a company or the commencement of business operations in more than 44 cases. This corresponds to an outstanding start-up rate of over 77 per cent. In addition, the respective start-ups have already been able to raise over two billion euros from investors and development partners. Particularly successful were, for example, BioNTech with the COVID-19 vaccine, Ethris GmbH with a new class of mRNA therapeutics, iThera Medical with imaging technologies, Corimmun with a partial sale to Janssen-Cilag, Rigontec (cancer immunotherapy) with the acquisition for a three-digit million euro amount by the pharmaceutical group MSD, CatalYm (cancer therapy) with the acquisition of 100 million euros in venture capital and Seamless Therapeutics (genome editing) with seed financing of eight million euros.